# A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

> **NCT05405660** · PHASE2 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 196 (actual)

## Conditions studied

- Chronic Inducible Urticaria

## Interventions

- **BIOLOGICAL:** barzolvolimab
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05405660
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2024-06-12
- **Final completion:** 2025-09-12
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405660, "A Study of CDX-0159 in Patients With Chronic Inducible Urticaria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05405660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*